The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10366 malaria professionals are enjoying the free benefits of MalariaWorld today

Scientific Articles

Host Response and Inflammation: Neutralization of Malaria Glycosylphosphatidylinositol In Vitro by Serum IgG from Malaria-Exposed Individuals

August 18, 2010 - 14:28 -- Patrick Sampao
Author(s): 
Brian de Souza J., Manohursingh R., et al
Reference: 
Infect. Immun., Sep 2010; 78: 3920 - 3929.

In conclusion, we have established an in vitro assay to test the toxin-neutralizing activities of antimalarial antibodies and have shown that anti-GPI antibodies from malaria-immune individuals are able to neutralize GPI-induced macrophage activation; however, the clinical relevance of anti-GPI antibodies remains to be proven, given that malarial schizonts contain other proinflammatory moieties, in addition to GPI.

Medical Treatment: 

Discovery of Potent Small-Molecule Inhibitors of Multidrug-Resistant Plasmodium falciparum Using a Novel Miniaturized High-Throughput Luciferase-Based Assay

August 18, 2010 - 13:09 -- Kabogo Ndegwa
Author(s): 
Edinson Lucumi, Claire Darling, Doron C. Greenbaum, et al
Reference: 
Antimicrobial Agents and Chemotherapy, September 2010, p. 3597-3604, Vol. 54, No. 9

Malaria is a global health problem that causes significant mortality and morbidity, with more than 1 million deaths per year caused by Plasmodium falciparum. Most antimalarial drugs face decreased efficacy due to the emergence of resistant parasites, which necessitates the discovery of new drugs.

Medical Treatment: 

Defining the Role of Mutations in Plasmodium vivax Dihydrofolate Reductase-Thymidylate Synthase Gene Using an Episomal Plasmodium falciparum Transfection System

August 18, 2010 - 13:05 -- Kabogo Ndegwa
Author(s): 
Alyson M. Auliff, John H. Adams, Michael T. O'Neil, and Qin Cheng
Reference: 
Antimicrobial Agents and Chemotherapy, September 2010, p. 3927-3932, Vol. 54, No. 9

Plasmodium vivax resistance to antifolates is prevalent throughout Australasia and is caused by point mutations within the parasite dihydrofolate reductase (DHFR)-thymidylate synthase. Several unique mutations have been reported in P. vivax DHFR, and their roles in resistance to classic and novel antifolates are not entirely clear due, in part, to the inability to culture P. vivax in vitro.

Medical Treatment: 

Investigations into the Role of the Plasmodium falciparum SERCA (PfATP6) L263E Mutation in Artemisinin Action and Resistance

August 18, 2010 - 12:52 -- Kabogo Ndegwa
Author(s): 
Stephanie Gaw Valderramos, Daniel Scanfeld, Anne-Catrin Uhlemann, David A. Fidock, and Sanjeev Krishna
Reference: 
Antimicrobial Agents and Chemotherapy, September 2010, p. 3842-3852, Vol. 54, No. 9

Artemisinin-based combination therapies (ACTs) are highly effective for the treatment of Plasmodium falciparum malaria, yet their sustained efficacy is threatened by the potential spread of parasite resistance.

Medical Treatment: 

Amodiaquine Resistance in Plasmodium falciparum Malaria in Afghanistan Is Associated with the pfcrt SVMNT Allele at Codons 72 to 76

August 18, 2010 - 12:48 -- Kabogo Ndegwa
Author(s): 
Khalid Beshir, Colin J. Sutherland, Ioannis Merinopoulos, Naeem Durrani, Toby Leslie, Mark Rowland, and Rachel L. Hallett
Reference: 
Antimicrobial Agents and Chemotherapy, September 2010, p. 3714-3716, Vol. 54, No. 9

Mutations in the Plasmodium falciparum genes pfcrt and pfmdr1 are selected by amodiaquine treatment in Africa.

Country: 

Absence of Association between Piperaquine In Vitro Responses and Polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe Genes in Plasmodium falciparum

August 18, 2010 - 12:43 -- Kabogo Ndegwa
Author(s): 
Sébastien Briolant, Maud Henry, Claude Oeuvray, Rémy Amalvict, Eric Baret, Eric Didillon, Christophe Rogier, and Bruno Pradines
Reference: 
Antimicrobial Agents and Chemotherapy, September 2010, p. 3537-3544, Vol. 54, No. 9

We have analyzed the profiles of 23 of Plasmodium falciparum strains for their in vitro chemosusceptibilities to piperaquine (PPQ), dihydroartemisinin (DHA), chloroquine, monodesethylamodiaquine, quinine, mefloquine, lumefantrine, atovaquone, pyrimethamine, and doxycycline (DOX) in association with polymorphisms in genes involved in quinoline resistance (Plasmodium falciparum crt [pfcrt], pfmdr1, pfmrp, and pfnhe).

Medical Condition: 

Open Access | Combined measurement of soluble and cellular ICAM-1 among children with Plasmodium falciparum malaria in Uganda

August 18, 2010 - 12:39 -- Kabogo Ndegwa
Author(s): 
Cserti-Gazdewich CM, Dzik WH, Erdman L, Ssewanyana I, Dhabangi A, Musoke C, Kain KC
Reference: 
Malaria Journal 2010, 9:233 (16 August 2010)

In this cohort of children with P. falciparum malaria, sICAM-1 levels were associated with severity-of-illness. Patients with UM had higher monocyte ICAM-1 expression consistent with a role for monocyte ICAM-1 in immune clearance during non-severe malaria.

Person: 
Country: 
Medical Condition: 

Plasmodium falciparum immunodetection in bone remains of members of the Renaissance Medici family (Florence, Italy, sixteenth century)

August 17, 2010 - 13:52 -- Patrick Sampao
Author(s): 
Gino Fornaciari, Valentina Giuffra, Ezio Ferroglio, Sarah Gino, Raffaella Bianucci
Reference: 
Transactions of the Royal Society of Tropical Medicine and Hygiene, Volume 104, Issue 9, September 2010, Pages 583-587

Our findings provide the first modern laboratory evidence of the presence of P. falciparum ancient proteins in the skeletal remains of four members of the Medici family. We confirm the clinical diagnosis of the court physicians, using modern methods.

Country: 
City: 
Medical Condition: 
Medical Treatment: 

Open Access | Examining appropriate diagnosis and treatment of malaria: availability and use of rapid diagnostic tests and artemisinin-based combination therapy in public and private health facilities in south east Nigeria

August 17, 2010 - 13:46 -- Patrick Sampao
Author(s): 
Uzochukwu BS, Chiegboka LO, Enwereuzo C, Nwosu U, Okorafor D, Onwujekwe OE, Uguru NP, Sibeudu FT, Ezeoke OP
Reference: 
BMC Public Health 2010, 10:486 (16 August 2010)

The study was undertaken in Enugu state, southeast Nigeria in March 2009. Data was collected from heads of 74 public and private health facilities on the availability and use of RDTs and ACTs. Also, the availability of RDTs and the types of ACTs that were available in the facilities were documented.

Medical Condition: 
Medical Treatment: 

A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice

August 16, 2010 - 14:24 -- Patrick Sampao
Author(s): 
Fernanda G., Daniel Y., et al
Reference: 
Vaccine, Volume 28, Issue 38, 31 August 2010, Pages 6183-6190

These results demonstrate that a recombinant protein containing PvAMA-1 DII is immunogenic when administered in different adjuvant formulations, and indicate that this region of the AMA-1 protein should continue to be evaluated as part of a subunit vaccine against vivax malaria.

Product: 
Medical Treatment: 

Pages

Subscribe to Scientific Articles